NCT01342835

Brief Summary

The investigators hypothesize that patients anesthetized with sevoflurane have more pain, postoperatively, than those anesthetized with propofol.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P75+ for phase_1 postoperative-pain

Timeline
Completed

Started Sep 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 20, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 27, 2011

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
Last Updated

April 27, 2011

Status Verified

September 1, 2010

Enrollment Period

4 months

First QC Date

April 20, 2011

Last Update Submit

April 26, 2011

Conditions

Keywords

propofolsevofluranepostoperative painchildren

Outcome Measures

Primary Outcomes (1)

  • postoperative pain

    The Faces Pain Scale (FPS) (from five face drawings: 0 = no pain, 5 = extreme pain) is used to assess pain severity

    120 minutes

Secondary Outcomes (2)

  • recovery time

    120 minutes

  • adverse effects

    0-120 minutes

Study Arms (2)

drug: propofol

ACTIVE COMPARATOR

Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.

Drug: Propofol

Sevoflurane group:sevoflurane

ACTIVE COMPARATOR

Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.

Drug: Propofol

Interventions

The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.

Also known as: Diprivan, Sevorane
Sevoflurane group:sevofluranedrug: propofol

Eligibility Criteria

Age3 Years - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Patient is 3- 6 years old
  • Patient is scheduled for hernia repair surgery at University Clinical center of Kosovo Patients is ASA I/II Patient meets criteria to receive either propofol or sevoflurane anesthesia Patient's parent/guardian provides written consent

You may not qualify if:

  • allergy to any of the drugs
  • preoperative anxiety
  • postoperative agitation
  • ASA physical status \>II

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Clinical Center of Kosovo

Pristina, Kosovo, 10000, Serbia

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Interventions

PropofolSevoflurane

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

PhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsMethyl EthersEthersHydrocarbons, FluorinatedHydrocarbons, Halogenated

Study Officials

  • Antigona Hasani, MD,MSC

    University Clinical Centre of Kosova

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Antigona Hasani, MD, MSC

CONTACT

Antiogna Hasani

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 20, 2011

First Posted

April 27, 2011

Study Start

September 1, 2010

Primary Completion

January 1, 2011

Study Completion

July 1, 2011

Last Updated

April 27, 2011

Record last verified: 2010-09

Locations